Santhera Pharmaceuticals reported preliminary unaudited revenues for the year 2017. The company reported an increase of 21% year-on-year in net revenues to CHF 22.9 million compared to 2016 net sales of CHF 19.0 million, from sales of its lead product Raxone(R) for the treatment of Leber's hereditary optic neuropathy (LHON).

For 2017, the company anticipates a net loss of CHF 50 million to CHF 55 million.

For 2018, the company expects net sales of Raxone for the currently approved indication LHON to reach CHF 28 to 30 million.